ziyuglycoside ii profile

ziyuglycoside II: isolated from Sanguisorba officinalis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Sanguisorba	genus	A plant genus of the family ROSACEAE. Members contain sanguiin.[MeSH]	Rosaceae	The rose plant family in the order ROSALES and class Magnoliopsida. They are generally woody plants. A number of the species of this family contain cyanogenic compounds.[MeSH]

ID Source	ID
PubMed CID	71773126
CHEMBL ID	4072747
SCHEMBL ID	22028779
MeSH ID	M000594914

Synonym
S9161
35286-59-0
ziyuglycoside ii
AC-34128
AKOS032948682
ziyuglycosideii
mfcd17214911
HY-N0332
CHEMBL4072747
CS-0008894
CCG-270205
MS-30662
gouguside 1
SCHEMBL22028779
(1r,2r,4as,6ar,6as,6br,8ar,10s,12ar,14bs)-1-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-10-[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
DTXSID901316548
3.beta.,19.alpha.-dihydroxyurs-12-en-28-oic acid 3-o-.alpha.-l-arabinopyranoside
(1r,4as,6br,10s,12ar,14bs)-1-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-10-(((2s,3r,4s,5r)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yl)oxy)-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2h)-carboxylic acid
3-o-.alpha.-l-arabinopyranosylpomolic acid
8AXK3E8B87
pomolic acid 3-o-.alpha.-l-arabinopyranoside
urs-12-en-28-oic acid, 3-(.alpha.-l-arabinopyranosyloxy)-19-hydroxy-, (3.beta.)-
3.beta.-o-.alpha.-l-arabinopyranosyl-19.alpha.-hydroxyurs-12-en-28-oic acid
zigu-glucoside ii

Excerpt	Reference	Relevance
" This method was then successfully applied to the preclinical pharmacokinetic studies of ziyuglycoside I and ziyuglycoside II."	( Development and validation of a quantification method for ziyuglycoside I and II in rat plasma: Application to their pharmacokinetic studies. Fu, H; Kang, D; Liang, Y; Rao, T; Shao, Y; Wang, G; Wang, Q; Xiao, J; Xie, L; Ye, W; Zhou, L, 2015)	0.42

Excerpt	Reference	Relevance
" The bioavailability of 29 was significantly improved in comparison with its aglycon."	( Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid. Chen, C; Cheng, K; Dai, L; Hu, K; Li, H; Liu, L; Sun, H; Wen, X; Xu, Q; Yuan, H, 2021)	0.62

Bioassays (12)

Assay ID	Title	Year	Journal	Article
AID1728066	Activation of AMPK in human Huh-7 cells assessed as increase in AMPK phosphorylation at Thr172 residue at 10 uM measured after 12 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
AID1496179	Cytotoxicity against rat RBL2H3 cells at 5 and 20 uM after 24 hrs by MTS assay	2018	Bioorganic & medicinal chemistry letters, 07-01, Volume: 28, Issue:12	Anti-allergic inflammatory components from Sanguisorba officinalis L.
AID1496181	Anti-inflammatory activity in PMA/A23187-stimulated rat RBL2H3 cells assessed as reduction of beta-hexosaminidase secretion preincubated for 1 hr followed by PMA/A23187 stimulation for 1 hr using 4-nitrophenyl-N-acetyl-beta-D-glucosaminide substrate	2018	Bioorganic & medicinal chemistry letters, 07-01, Volume: 28, Issue:12	Anti-allergic inflammatory components from Sanguisorba officinalis L.
AID1496185	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production at 20 uM preincubated for 2 hrs followed by LPS addition measured after 24 hrs by ELISA	2018	Bioorganic & medicinal chemistry letters, 07-01, Volume: 28, Issue:12	Anti-allergic inflammatory components from Sanguisorba officinalis L.
AID1496180	Cytotoxicity against mouse RAW264.7 cells at 5 and 20 uM after 24 hrs by MTS assay	2018	Bioorganic & medicinal chemistry letters, 07-01, Volume: 28, Issue:12	Anti-allergic inflammatory components from Sanguisorba officinalis L.
AID1436764	Anticomplement activity in New Zealand White rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway preincubated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 min	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Anticomplement triterpenoids from the roots of Ilex asprella.
AID1436763	Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway preincubated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometer	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Anticomplement triterpenoids from the roots of Ilex asprella.
AID1496186	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS addition measured after 24 hrs by Griess method	2018	Bioorganic & medicinal chemistry letters, 07-01, Volume: 28, Issue:12	Anti-allergic inflammatory components from Sanguisorba officinalis L.
AID1496178	Anti-inflammatory activity in PMA/A23187-stimulated rat RBL2H3 cells assessed as reduction of IL4 secretion preincubated for 2 hrs followed by PMA/A23187 stimulation for 18 hrs by ELISA	2018	Bioorganic & medicinal chemistry letters, 07-01, Volume: 28, Issue:12	Anti-allergic inflammatory components from Sanguisorba officinalis L.
AID1496182	Anti-inflammatory activity in IgE sensitized and DNP-BSA-stimulated rat RBL2H3 cells assessed as reduction of IL4 secretion preincubated for 2 hrs followed by DNP-BSA stimulation for 18 hrs by ELISA	2018	Bioorganic & medicinal chemistry letters, 07-01, Volume: 28, Issue:12	Anti-allergic inflammatory components from Sanguisorba officinalis L.
AID1496184	Inhibition of NFkappaB nuclear translocation in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated for 2 hrs followed by LPS-induction by DAPI-staining based immunofluorescence microscopic method	2018	Bioorganic & medicinal chemistry letters, 07-01, Volume: 28, Issue:12	Anti-allergic inflammatory components from Sanguisorba officinalis L.
AID1496183	Inhibition of PMA-induced NFkappaB P65 activation (unknown origin) expressed in human HEK293T cells transfected with pNF-kappaB-SEAP preincubated for 2 hrs followed by PMA stimulation measured after overnight incubation by by NFkappaB reporter gene assay	2018	Bioorganic & medicinal chemistry letters, 07-01, Volume: 28, Issue:12	Anti-allergic inflammatory components from Sanguisorba officinalis L.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	14 (70.00)	24.3611
2020's	6 (30.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (5.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (95.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
celecoxib [no description available]	2.17	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.08	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.31	1	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
glycyrrhetinic acid [no description available]	2.31	1	cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid	immunomodulator; plant metabolite
oleanolic acid [no description available]	2.31	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
glycyrrhizic acid glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.	2.31	1	enone; glucosiduronic acid; pentacyclic triterpenoid; tricarboxylic acid; triterpenoid saponin	EC 3.4.21.5 (thrombin) inhibitor; plant metabolite
ursolic acid [no description available]	2.61	2	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
betulinic acid [no description available]	2.31	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
hederagenin [no description available]	2.31	1	dihydroxy monocarboxylic acid; pentacyclic triterpenoid; sapogenin	plant metabolite
madecassic acid [no description available]	2.31	1	monocarboxylic acid; pentacyclic triterpenoid; tetrol	antioxidant; plant metabolite
maslinic acid (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria	2.31	1	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite
asiatic acid [no description available]	2.31	1	monocarboxylic acid; pentacyclic triterpenoid; triol	angiogenesis modulating agent; metabolite
oleanolic acid 3-o-monoglucuronide oleanolic acid 3-O-monoglucuronide: structure given in first source	2.31	1	beta-D-glucosiduronic acid
scoparianoside b scoparianoside B: isolated from the fruit of Japanese Kochia scoparia; structure given in first source	2.31	1	triterpenoid saponin
pomolic acid pomolic acid: from Rosa woodsii & Hyptis capitata; structure in first source	2.15	1	triterpenoid	metabolite
bay 11-7082 (E)-3-tosylacrylonitrile : A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells.	2.17	1	nitrile; sulfone	apoptosis inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor
beta-escin [no description available]	5.45	17
corosolic acid [no description available]	2.31	1	triterpenoid	metabolite
ilekudinol b ilekudinol B: stimulates glucose uptake; from Weigela subsessilis; structure in first source	2.15	1
kalopanax saponin b kalopanax saponin B: isolated from Kalopanax septemlobus; structure given in first source. kalopanaxsaponin B : A triterpenoid saponin with hederagenin as the aglycone part. It has been isolated from the stem bark of Kalopanax pictus.	2.31	1	carboxylic ester; pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; plant metabolite
ginsenoside ro ginsenoside Ro: from ginseng; RN given refers to ginsenoside Ro, (all-D)-isomer	2.31	1	triterpenoid saponin	metabolite
rutundic acid rutundic acid: isolated from the leaves of Hex pupurea; structure in first source	2.15	1	triterpenoid	metabolite
23-hydroxyursolic acid 23-hydroxyursolic acid: from medicinal plants of the Rubiaceae family; structure in first source. 23-hydroxyursolic acid : A pentacyclic triterpenoid that is ursolic acid substituted by an additional hydroxy group at position 23. It has been isolated from Lagerstroemia speciosa and Juglans sinensis.	2.15	1	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
madecassoside [no description available]	2.31	1	carboxylic ester; pentacyclic triterpenoid; trisaccharide derivative; triterpenoid saponin	anti-inflammatory agent; antioxidant; antirheumatic drug; plant metabolite; vulnerary
ziyuglycoside i ziyuglycoside I: isolated from the leaves of Hex pupurea; structure in first source	9.51	6

Condition	Relationship Strength	Studies
Extravascular Hemolysis [description not available]	2.15	1
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.15	1
Innate Inflammatory Response [description not available]	2.17	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.17	1
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.21	1
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.21	1
Hepatocellular Carcinoma [description not available]	7.25	1
Cancer of Liver [description not available]	2.25	1
Invasiveness, Neoplasm [description not available]	2.25	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.25	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.25	1
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	7.25	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.25	1
Rotavirus Infections Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Leukocytopenia [description not available]	2.25	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	7.25	1
Cancer of Digestive System [description not available]	2.31	1
Digestive System Neoplasms Tumors or cancer of the DIGESTIVE SYSTEM.	2.31	1
Angiogenesis, Pathologic [description not available]	2.15	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.17	1
Cancer of Colon [description not available]	2.21	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.21	1
Carcinoma, Anaplastic [description not available]	2.49	2
Cancer of Stomach [description not available]	2.08	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	7.49	2
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.08	1
Breast Cancer [description not available]	7.1	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.1	1
Diabetes Mellitus, Adult-Onset [description not available]	2.11	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.11	1

ziyuglycoside ii

Description

Cross-References

Synonyms (24)

Research Excerpts

Pharmacokinetics

Bioavailability

Bioassays (12)

Research

Studies (20)

Study Types

ziyuglycoside ii

Description

Related Flora

Cross-References

Synonyms (24)

Research Excerpts

Pharmacokinetics

Bioavailability

Bioassays (12)

Research

Studies (20)

Study Types

Related Drugs (25)

Related Conditions (31)